A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 9/00 (2006.01) A61K 9/08 (2006.01) A61K 9/14 (2006.01) A61K 9/19 (2006.01) A61K 9/20 (2006.01) A61K 9/48 (2006.01) A61K 31/397 (2006.01) A61K 31/424 (2006.01) A61P 25/16 (2006.01) A61P 25/28 (2006.01)
Patent
CA 2758029
The present invention generally relates to use of a stable solid pharmaceutical compositions that includes a clavu-lanate as the pharmaceutically active ingredients in an immediate-release or an extended-release solid dosage form. The composi-tion can be used in a method of treating a neurodegenerative disease, providing neuroprotection, or preventing neuronal cell loss or death. Exemplary neurodegenerative diseases include Parkinson's disease, Alzheimer's disease and multiple sclerosis.
La présente invention porte d'une manière générale sur l'utilisation de compositions pharmaceutiques solides stables qui comprennent un clavulanate en tant qu'ingrédients pharmaceutiquement actifs dans une forme posologique solide à libération immédiate ou à libération étendue. La composition peut être utilisée dans le procédé de traitement d'une maladie neurodégénérative, fournissant une neuroprotection ou prévenant une perte ou une mort cellulaire neuronale. Des maladies neurodégénératives à titre d'exemple comprennent la maladie de Parkinson, la maladie d'Alzheimer et la sclérose en plaques.
Ahn Chang Ho
Huh Youngbuhm
Kim Deog Joong
Lee Young Bok
Scholtz Edward Carl
Gowling Lafleur Henderson Llp
Rexahn Pharmaceuticals Inc.
LandOfFree
Clavulanate formulation for neuroprotection and treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Clavulanate formulation for neuroprotection and treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Clavulanate formulation for neuroprotection and treatment of... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1746935